Search by Drug Name or NDC

    NDC 55513-0207-01 MVASI 400 mg/16mL Details

    MVASI 400 mg/16mL

    MVASI is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Amgen Inc. The primary component is BEVACIZUMAB.

    Product Information

    NDC 55513-0207
    Product ID 55513-207_11156d95-bd9a-4d3c-bff3-371869ea13e8
    Associated GPIs 21335020202030
    GCN Sequence Number 077715
    GCN Sequence Number Description bevacizumab-awwb VIAL 25 MG/ML INTRAVEN
    HIC3 V1X
    HIC3 Description ANTINEOPLAST HUM VEGF INHIBITOR RECOMB MC ANTIBODY
    GCN 43835
    HICL Sequence Number 044500
    HICL Sequence Number Description BEVACIZUMAB-AWWB
    Brand/Generic Brand
    Proprietary Name MVASI
    Proprietary Name Suffix n/a
    Non-Proprietary Name bevacizumab-awwb
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, SOLUTION
    Route INTRAVENOUS
    Active Ingredient Strength 400
    Active Ingredient Units mg/16mL
    Substance Name BEVACIZUMAB
    Labeler Name Amgen Inc
    Pharmaceutical Class Vascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA], Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA761028
    Listing Certified Through 2024-12-31

    Package

    NDC 55513-0207-01 (55513020701)

    NDC Package Code 55513-207-01
    Billing NDC 55513020701
    Package 1 VIAL in 1 CARTON (55513-207-01) / 16 mL in 1 VIAL
    Marketing Start Date 2018-06-01
    NDC Exclude Flag N
    Pricing Information N/A